Cemiplimab as maintenance therapy for advanced vulvar cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether continuing treatment with cemiplimab (an immunotherapy drug) after initial chemotherapy can help keep vulvar cancer from growing, compared to standard supportive care. It is for people whose cancer is stable or improved after their first round of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You have vulvar cancer (squamous cell type) that is advanced, has spread, or has come back and cannot be cured with standard treatments.
- You have completed at least 4 cycles of first-line platinum-based chemotherapy (such as carboplatin or cisplatin) and your cancer has not grown after it.
- You have not received certain types of immunotherapy (like PD-1 or PD-L1 inhibitors) before.
- You do not have significant autoimmune disease, untreated brain tumors, or active infections like HIV, hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) can keep penile cancer from growing after you've finished your first round of chemotherapy. Participants will either get cemiplimab as a maintenance treatment or standard supportive care to see which helps better.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Hear when a new Vulvar Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.